|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sixteen patients starting endocrine treatment for de novo or progressive breast cancer bone metastases were prospectively recruited to undergo [<sup>18</sup>F]fluoride and [<sup>18</sup>F]FDG PET/CT scans before and 8 weeks after treatment.
|
30250989 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
False-positive bone lesions mimicking bone metastases (bone pseudometastasis) on F-FDG PET/CT have often been reported in patients with esophageal cancer.
|
31107756 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sensitivity of bone marrow involvement in bone metastases positive patients on <sup>18</sup>F-FDG PET/CT was 75% (3/4), and the specificity was 100% (22/22).
|
31104192 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that FDG-PET evaluation in metastatic bone lesions could be useful to predict initial pain and subsequent clinical outcomes of local bone status in initially diagnosed lung cancer patients with bone metastasis.
|
30883012 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Stepwise Approach to Identify the Clinical Role of 18F-FDG PET/CT in Patients With Suspicious Bone Metastasis From an Unknown Primary Site.
|
31274555 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sensitivity, specificity, accuracy, and positive and negative predictive values of <sup>18</sup>F-FDG PET/CT for detecting chest and bone metastases were comparable to those of conventional imaging (<i>p</i> > .1).
|
31274365 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Active Bone Marrow With Focal FDG Accumulation Mimicking Bone Metastasis With a Case of Early Esophageal Cancer.
|
29504964 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diffuse hepatic epithelioid hemangioendothelioma with multiple splenic metastasis and delayed multifocal bone metastasis after liver transplantation on FDG PET/CT images: A case report.
|
29851777 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG PET-CT seems to be superior to bone scan in the detection of bone metastasis in all districts except skull bones.
|
29620679 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
99mTc-MDP-BS, 18F-FDG-PET/CT and 18F-FCH-PET/CT occurred as comparable imaging methods in bone metastases detection in the prostate cancer patients and provide complementary clinical conclusions.
|
29681049 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The specificity, overall accuracy, and PPV of whole-body DWIBS are significantly lower than those of <sup>18</sup>F-FDG PET/CT because of a high incidence of false-positive findings particularly for detecting bone metastasis, whereas whole-body DWIBS shows a similar level of sensitivities for detecting lymph node and bone metastases to those of <sup>18</sup>F-FDG PET/CT.
|
29667143 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dilated Internal Thoracic Vertebral Venous Plexus Simulating Bone Metastases on FDG PET/CT.
|
29215407 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In prostate and breast cancer, WB-MRI-DWI is useful in assessing the response of bone lesions to therapy and to detecting early non-responders, while in lung cancer the method shows a similar sensitivity to 18F-FDG PET/CT in the detection of bone metastases.
|
29987207 |
2018 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the safety and efficacy of <sup>18</sup>F-FDG PET/CT in guiding biopsy of bone metastases in patients with advanced lung cancer.
|
27444682 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interestingly, 18F-FDG-PET/CT showed that early eradication of individual BM metastasis by systemic treatment precluded development of bone metastasis.
|
28884133 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of our case report is to emphasize the role of FDG PET/CT in the assessment of tumor recurrence and extracranial bone metastases from anaplastic astrocytoma.
|
28591062 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
FDG PET/CT showed multiple bone metastases in addition to nerve involvement.
|
28288046 |
2017 |
|
Secondary malignant neoplasm of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
<sup>18</sup>FDG PET/PET-CT is superior to BS for diagnosing bone metastases in nasopharyngeal cancer patients.<sup>18</sup>FDG PET/PET-CT may enhance the diagnosis of bone metastases and provide more accurate information for the optimal management of nasopharyngeal cancer.
|
28938677 |
2017 |